Please login to the form below

Not currently logged in
Email:
Password:

ABPI's Stephen Whitehead steps down

Leaves the UK pharma trade body after four years as its CEO

Stephen WhiteheadThe Association of the British Pharmaceutical Industry's (ABPI) Stephen Whitehead has left the organisation after serving as CEO for four years.

Speaking on behalf of the board ABPI president John Kearney said: “We want to thank Stephen for the very significant contribution he has made to the transformation and success of the ABPI.

“We wish Stephen the best for the future.”

Whitehead joined the UK trade body in 2011, taking over from Richard Barker, and brought senior experience from Barclays and Allied Domecq.

Earlier in his career, Whitehead spent ten years at GlaxoSmithKline and Eli Lilly at UK, European and international levels.

Once he moved back to pharma he quickly made an impact at the ABPI and in 2012 picked up Healthcare Communiquétor of the Year at the Communiqué Awards in recognition of his positive impact at the Association.

The ABPI said it would now begin searching for a new CEO and in the meantime Alison Clough would continue as acting CEO.

2nd October 2015

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics